EP1305289A2 - Neue heteroaryl-derivate und deren verwendung als antitumormittel - Google Patents
Neue heteroaryl-derivate und deren verwendung als antitumormittelInfo
- Publication number
- EP1305289A2 EP1305289A2 EP01960509A EP01960509A EP1305289A2 EP 1305289 A2 EP1305289 A2 EP 1305289A2 EP 01960509 A EP01960509 A EP 01960509A EP 01960509 A EP01960509 A EP 01960509A EP 1305289 A2 EP1305289 A2 EP 1305289A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- radical
- substituted
- mono
- alkylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to new heteroaryl derivatives of the general formula 1, their production and use as medicaments, in particular for the treatment of tumors.
- new pyridine derivatives according to general formula 1
- R, Ri, R2, 3 can optionally be bonded to the pyridine carbon atoms C 2 to C 6 , are the same or different and, independently of one another, hydrogen, straight-chain or branched (C ⁇ -C ⁇ ) alkyl, (C3-C7) - cycloalkyl, straight-chain or branched (-C-C8) alkylcarbonyl, preferably acetyl, straight-chain or branched
- Halogen aryl- (-C-Cs) -alkoxy, preferably benzyloxy or phenyl-ethyloxy, nitro, amino, mono- (CrC 4 ) -alkylamino, di- (-C-C 4 ) -alkylamino, (C ⁇ -C ⁇ ) -alkoxycarbonyl -amino, (Ci-CeJ-alkoxycarbonylamino ⁇ CrC ⁇ ) - alkyl, cyano, straight-chain or branched cyano- (-C-C-6) alkyl, Carboxy, (Ci-CsJ-alkoxycarbonyl, substituted with one or more fluorine atoms (-CC 4 ) -alkyl, preferably the trifluoromethyl group, carboxy- (-C- 8 ) -alkyl or (C C8) -alkoxycarbonyl- (-C-C 6 ) alkyl, (C 2 -C 6
- P, Q independently of one another represent oxygen or in each case two hydrogen atoms (ie -CH 2 -);
- X is nitrogen or CR 5 , where R 5 is hydrogen or (-CC 6 ) alkyl
- R 4 is a straight-chain or branched (-CC 2 o) -alkyl radical which can be saturated or unsaturated with one to three double and / or triple bonds and which is unsubstituted or optionally on the same or different C atoms, two or more aryl, heteroaryl,
- Alkoxycarbonyl with one or more fluorine atoms substituted straight-chain or branched (C ⁇ -C6) -alkyl, preferably trifluoromethyl, hydroxy, straight-chain or branched (C ⁇ -C ⁇ ) -alkoxy, preferably methoxy or ethoxy, with adjacent oxygen atoms also being substituted by (C 1 - C2) - alkylene groups, preferably a methylene group, can be linked,
- the compounds of the general formula (1) according to the invention which have one or more chiral centers and which occur as racemates can be separated into their optical isomers, ie enantiomers or diastereomers, by methods known per se.
- the separation can be carried out by column separation on chiral phases or by recrystallization from an optically active solvent or using an optically active acid or base or by derivatization with an optically active reagent, such as, for example, an optically active alcohol, and subsequent elimination of the rest.
- pyridine derivatives according to the invention of the general formula (1) can be converted into their salts with inorganic or organic acids, in particular for their pharmaceutical use into their physiologically tolerable salts.
- acids for this are hydrochloric acid,
- Hydrobromic acid sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, acetic acid, tartaric acid, malic acid, embonic acid, malonic acid, trifluoroacetic acid or maleic acid.
- the compounds of the formula (1) according to the invention can, if desired, be in their salts with inorganic or organic bases, in particular for pharmaceutical use in their physiological tolerable salts.
- bases which can be used here are sodium hydroxide, potassium hydroxide, calcium hydroxide, lysine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
- pyridine derivatives according to general formula 1 are provided, in which R, R1, R2, R3, X, Z, P, Q, n and m have the meanings given above and
- R 4 is a straight-chain or branched (-CC 2 o) -alkyl radical which can be saturated or unsaturated with one to three double and / or triple bonds and which is unsubstituted or optionally on the same or different C atoms, two or more aryl, heteroaryl, halogen, (C1-C6) alkoxy, amino, mono- (CC 4 ) alkylamino or di- (C1-C4) alkylamino may be substituted;
- a phenyl radical or a naphthyl radical each unsubstituted or one or more of the same or different with straight-chain or branched (-C-C 8 ) alkyl, (C 3 -C 7 ) cycloalkyl, halogen, cyano, ( C ⁇ -C 6 ) - Alkoxycarbonylamino, (C ⁇ -C6) alkoxy, carboxy, (C ⁇ -C ⁇ ) alkoxycarbonyl, with one or more fluorine atoms substituted straight-chain or branched (C ⁇ -C ⁇ ) alkyl, preferably trifluoromethyl, hydroxy, straight-chain or branched (-C-Cs) alkoxy, preferably methoxy or ethoxy, where adjacent oxygen atoms can also be linked by (-C-C 2 ) alkylene groups, preferably a methylene group, benzyloxy, nitro, amino, mono-CrC ⁇ -Alkylamino,
- Aryl which in turn is unsubstituted or one or more identical or different with straight-chain or branched (C ⁇ -C ⁇ ) alkyl, (C3-C7) cycloalkyl, carboxy, straight-chain or branched (C ⁇ -C ⁇ ) alkoxycarbonyl, with trifluoromethyl, Hydroxy, straight-chain or branched (-CC 8 ) alkoxy, preferably methoxy or ethoxy, benzyloxy, nitro, amino, mono- (-C-C4)
- Alkylamino, di (C 1 -C 4 ) alkylamino, cyano, straight-chain or branched cyano (C 1 -C 6 ) alkyl is substituted can be substituted, a 2-, 4-, 5- or 6-pyrimidinyl radical or 2-, 4-, 5- or 6-pyrimidinyl- (Ci -C 4 ) alkyl radical, where the (Ci -C4) alkyl ⁇
- Halogen nitro, amino, mono- (-C-C 6 ) alkylamino, di- (C ⁇ -C 6 ) alkylamino, hydroxy, (Ci-CeJ-alkoxy, benzyloxy, carboxy, (CrC 6 ) -alkoxycarbonyl, (C ⁇ -C 6 ) alkoxycarbonylamino or mono- or polysubstituted with fluorine (Ci -C 6 ) alkyl, preferably trifluoromethyl, (C 6 -C ⁇ o) aryl, or (C 6 -C ⁇ 0 ) aryl (Ci-C ⁇ J alkyl may be substituted;
- (-C-C 6 ) alkyl halogen, nitro, amino, mono- (C ⁇ -C 6 ) alkylamino, di- (CrC 6 ) alkylamino, hydroxy, (C ⁇ -C ⁇ ) alkoxy, benzyloxy, carboxy, ( Ci-C ⁇ ) - alkoxycarbonyl, (-C-Ce) -alkoxycarbonylamino or one or more fluorine-substituted (Ci -C ⁇ J-alkyl, preferably trifluoromethyl, (C 6 -C 1 o) aryl, or (C 6 - C ⁇ o) aryl (C ⁇ -C ⁇ ) alkyl may be substituted;
- a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical or 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl- (C ⁇ - C 4) -alkyl radical, where the (Ci-C4) -alkyl radical can be unsubstituted or mono- or polysubstituted by identical or different (Ci -C ⁇ ) alkyl, halogen or oxo ( O) may be substituted and the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl
- Radical is unsubstituted or mono- to hexasubstituted by identical or different hydrogen, (C- ⁇ -C ⁇ ) alkyl, preferably methyl, particularly preferably 2-methyl, halogen, nitro, amino, mono- (dC 6) alkylamino, di- (-CC 6 ) - alkylamino, hydroxy, (-C-C ⁇ ) alkoxy, benzyloxy, carboxy, (Ci-C ⁇ ) - alkoxycarbonyl, (-C-C 6 ) alkoxycarbonylamino or one or more times with
- Fluorine-substituted (Ci -C ⁇ ) alkyl preferably trifluoromethyl, (C 6 -C ⁇ o) aryl, or (C 6 -C ⁇ o) aryl (C ⁇ -C 6 ) alkyl may be substituted;
- Carboxy, (-C-C ⁇ ) alkoxycarbonyl, (CrC ⁇ J-alkoxycarbonylamino or (C 1 -C 6 ) alkyl substituted one or more times with fluorine, preferably trifluoromethyl, (C 6 -C ⁇ o) aryl, or (C 6 -C ⁇ o) -Aryl- (-C-C6) alkyl may be substituted; a 2-, 6-, 8- or 9- [9H] -urinyl residue or 2-, 6-, 8- or 9- [9H] -purinyl- (Ci-C4) -alkyl residue, where the ( Ci -C 4 ) alkyl radical unsubstituted or substituted one or more times, identically or differently, with (Ci -C ⁇ ) alkyl, halogen or oxo ( 0) and which is 2-, 6-, 8- or 9- [9H] -Purinyl residue unsubstituted or mono-
- (d-C ⁇ ) alkyl may be substituted
- (Ci -C 6 ) alkyl preferably trifluoromethyl, (C 6 -C ⁇ o) aryl, or (C 6 -do) aryl- (d-C ⁇ ) alkyl may be substituted;
- a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl or 1-, 2-, 3-, 4-, 5-, 6-, 7- , 8- or 9-acridinyl- (-C -C 4 ) alkyl radical, where the (Ci -C6) alkyl radical is unsubstituted or one or more times the same or different with (Ci -C ⁇ ) - alkyl, halogen or Oxo ( 0) can be substituted and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl residue unsubstituted or one to eight times the same or different with hydrogen , (dC ⁇ ) -alkyl, halogen, nitro, amino, mono- (d-C ⁇ ) -alkylamino, di- (-C-C B ) -alkylamino, hydroxy, (C ⁇ -C 6 ) -alkoxy,
- a 2-, 3-, -4-, 5, - or 6-pyridyl radical where the 2-, 3 -, - 4-, 5, - or 6-pyridinyl radical is unsubstituted or one to four times the same or different with hydrogen, (-CC 6 ) -alkyl, halogen, nitro, amino, mono- (-C-C 6 ) -alkylamino, di- (-C-C 6 ) -alkylamino, hydroxy, (CrC 6 ) -alkoxy, Benzyloxy, carboxy, (-CC 6 ) - alkoxycarbonyl, (-CC 6 ) alkoxycarbonylamino or one or more times
- Fluorine substituted (Ci -C 6 ) alkyl preferably trifluoromethyl, (C ⁇ -C ⁇ o) aryl, or (C ⁇ -C ⁇ o) aryl (C ⁇ -C ⁇ ) alkyl may be substituted;
- (-C-C ⁇ ) alkyl may be substituted
- Alkyl preferably trifluoromethyl, (C ⁇ -C ⁇ o) aryl, or (C ⁇ -C ⁇ o) aryl- (C ⁇ -C6) - alkyl can be substituted;
- Benzthiazolyl radical unsubstituted or one to four times the same or different with hydrogen, (-CC 6 ) alkyl, halogen, nitro, amino, mono- (-C-C 6 ) - alkylamino, di- (-C-C 6 ) - Alkylamino, hydroxy, (-C-C 6 ) alkoxy, benzyloxy, carboxy, (dC ⁇ ) alkoxycarbonyl, (CrC ⁇ ) alkoxycarbonylamino or mono- or polysubstituted with fluorine (Ci -C 6 ) alkyl, preferably trifluoromethyl,
- (Ci -C 6 ) alkyl preferably trifluoromethyl, (C 6 -C ⁇ o) aryl, or (C 6 -C ⁇ o) aryl (C ⁇ -C ⁇ ) alkyl may be substituted;
- (dC ⁇ ) alkyl may be substituted
- Fluorine-substituted (Ci-C ⁇ ) alkyl preferably trifluoromethyl, (C 6 -C ⁇ o) aryl, or (C ⁇ -C ⁇ o) aryl- (-C-C ⁇ ) alkyl may be substituted;
- Alkoxycarbonylamino or mono- or polysubstituted with fluorine (Ci -C ⁇ ) - alkyl, preferably trifluoromethyl, (C 6 -C ⁇ o) aryl, or (C 6 -C ⁇ o) aryl (C ⁇ -C ⁇ ) - alkyl can be substituted ; a 1- or 5- [1H] tetrazolyl radical or 1- or 5- [1H] tetrazolyl- (-C -C ⁇ ) - alkyl radical, the (Ci -C ⁇ ) alkyl radical being unsubstituted or a - or several times the same or different with (Ci -C ⁇ ) alkyl, halogen or oxo ( 0) and the 1 - or 5- [1 H] tetrazolyl radical may be unsubstituted or substituted
- (d-C ⁇ ) alkyl may be substituted
- Fluoro-substituted (Ci-C6) alkyl preferably trifluoromethyl, (C6 -C ⁇ o) aryl, or (C 6 -C ⁇ o) aryl (C ⁇ -C6) alkyl may be substituted; means and the isomers, in particular tautomers, diastereomers and enantiomers, and the pharmaceutically acceptable salts, in particular acid addition salts thereof.
- pyridine derivatives according to the general formula (1) are provided, characterized in that R, R 1, R 2 , R 3 , X, Z, P, Q, n and m have the abovementioned meanings and R 4 is phenyl stands, which is unsubstituted or substituted with one to five identical or different (-CC 6 ) alkoxy groups, adjacent oxygen atoms may also be linked by (-C-C2) alkylene groups.
- pyridine derivatives according to the general formula (1) are provided, characterized in that R 4 has the meanings given above, R, R1, R2, R3 each represent a hydrogen atom, Z represents an oxygen atom and X represents a nitrogen atom , P and Q each represent two hydrogen atoms (i.e. -CH2-), m is zero and n represents the integer 2.
- pyridine derivatives according to the general formula (1) are provided, characterized in that R, R 1 , R 2 , R 3 , X, Z, P, Q, n and m have the meanings given above and R 4 represents 3,5-dimethoxyphenyl.
- pyridine derivatives according to the general formula (1) are provided, characterized in that R, R 1 , R 2 , R3 each for a hydrogen atom, Z for an oxygen atom, X for a nitrogen atom, P and Q each for two hydrogen atoms (i.e. -CH2-) stand, m is zero, n stands for the integer 2 and R 4 stands for a 3,5-dimethoxyphenyl radical.
- Z represents an oxygen or sulfur atom and Y for a leaving group such as halogen, hydroxy, (C1-C6) alkoxy preferably methoxy and ethoxy, -0-tosyl, -O Mesyl or imidazolyl, with an amine of the general formula (3),
- R4, X, P, Q, m and n have the meanings given above, if appropriate using diluents and auxiliaries to form the desired pyridine derivative.
- the starting compounds (2) and (3) are either commercially available or can be prepared by processes known per se.
- the starting materials (2) and (3) are valuable intermediates for the preparation of the pyridine derivatives of the formula (1) according to the invention.
- reaction temperature and reaction time are known from the literature or are known to the person skilled in the art on the basis of his specialist knowledge.
- the pyridine derivatives according to the invention according to the general formula (1) are suitable as medicaments, in particular as antitumor agents, for the treatment of mammals, in particular humans, but also for pets such as horses, cows, dogs, cats, rabbits, sheep, poultry and the like ,
- a method for combating tumors in mammals which is characterized in that at least one pyridine derivative according to the general formula (1) is administered to a mammal in an amount effective for tumor treatment.
- the therapeutically effective dose of the respective pyridine derivative according to the invention to be administered for the treatment depends, inter alia, on the type and stage of the tumor disease, the age and sex of the patient, the type of administration and the duration of the treatment. Administration can be oral, rectal, buccal (eg sublingual), parenteral (eg subcutaneous, intramuscular, intradermal or intravenous), topical or transdermal.
- Tumor treatment which are characterized in that they contain at least one pyridine derivative according to one of claims 1 to 5 or a pharmaceutically acceptable salt thereof as an active ingredient, optionally together with customary pharmaceutically acceptable auxiliaries, additives and carriers.
- These can be solid, semi-solid, liquid or aerosol preparations.
- Suitable solid preparations are, for example, capsules, powders, granules, tablets.
- Suitable semi-solid preparations are, for example, ointments, creams, gels, pastes, suspensions, oil-in-water and water-in-oil emulsions.
- Suitable liquid preparations are, for example, sterile aqueous preparations for parenteral administration which are isotonic with the patient's blood.
- the substance D-43411 was tested for its anti-proliferative activity in a proliferation test on established tumor cell lines.
- the test used determines the cellular dehydrogenase activity and enables a determination of the cell vitality and indirectly the cell number.
- the cell lines used are the human cervical carcinoma cell line KB / HeLa (ATCC CCL17), the murine lymphocytic leukemia L1210 (ATCC CCL-219), the human breast adenocarcinoma line MCF7 (ATCC HTB22) and the ovarian adenocarcinoma line SKOV-3 (ATCC CCB17) ). These are very well characterized, established cell lines obtained from ATCC and taken in culture.
- the adherent growing tumor cell lines HeLa / KB, SKOV-3 and MCF7 as well as the L1210 leukemia line growing in suspension were cultivated under standard conditions in the gassing incubator at 37 ° C, 5% C0 2 and 95% humidity.
- the adherent cells are detached with trypsin / EDTA and pelleted by centrifugation.
- the cell pellet is then resuspended in the RPMI culture medium in the appropriate cell number and converted into a 96-well microtiter plate.
- the plates are then cultivated overnight in the fumigation incubator.
- the test substances are prepared as stock solutions in DMSO and diluted with culture medium in the appropriate concentrations on test day 2.
- the substances in culture medium are then added to the cells and incubated for 45 hours in the fumigation incubator. Cells that are not treated with test substance serve as a control.
- XTT sodium 3 '- [1- (phenylaminocarbonyl) -3,4-tetrazolium] bis (4-methoxy-6-nitro) benzenesulfonic acid
- RPMI-1640 medium without phenol red
- PMS N-methyl dibenzopyrazine methyl sulfate
- PBS phosphate-buffered saline
- the XTT solution is mixed with the PMS solution in a ratio of 50: 1 (vol: vol) shortly before use.
- the cell plates are then incubated in the gassing incubator for a further 3 hours and the optical density (OD4gonm) is determined in the photometer.
- the percentage inhibition relative to the control is calculated using the determined OD49onm.
- the anti-proliferative effect is estimated using a regression analysis.
- (1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with intensive mixing. This powder mixture is filled into size 3 hard gelatin capsules on a capsule filling machine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10035908 | 2000-07-21 | ||
DE10035908A DE10035908A1 (de) | 2000-07-21 | 2000-07-21 | Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel |
PCT/EP2001/008262 WO2002008190A2 (de) | 2000-07-21 | 2001-07-18 | Neue heteroaryl-derivate und deren verwendung als antitumormittel |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1305289A2 true EP1305289A2 (de) | 2003-05-02 |
Family
ID=7649970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01960509A Withdrawn EP1305289A2 (de) | 2000-07-21 | 2001-07-18 | Neue heteroaryl-derivate und deren verwendung als antitumormittel |
Country Status (21)
Country | Link |
---|---|
US (1) | US6638935B2 (hu) |
EP (1) | EP1305289A2 (hu) |
JP (1) | JP2004516243A (hu) |
KR (1) | KR20030015894A (hu) |
CN (1) | CN1447796A (hu) |
AR (1) | AR032467A1 (hu) |
AU (2) | AU8198901A (hu) |
BG (1) | BG107506A (hu) |
BR (1) | BR0112711A (hu) |
CA (1) | CA2353353A1 (hu) |
DE (1) | DE10035908A1 (hu) |
HU (1) | HUP0300743A2 (hu) |
IL (1) | IL153931A0 (hu) |
MX (1) | MXPA03000596A (hu) |
NO (1) | NO20030302L (hu) |
NZ (1) | NZ524156A (hu) |
PL (1) | PL361354A1 (hu) |
RU (1) | RU2003105238A (hu) |
SK (1) | SK1942003A3 (hu) |
WO (1) | WO2002008190A2 (hu) |
ZA (1) | ZA200300545B (hu) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
MXPA04012959A (es) * | 2002-06-29 | 2005-05-16 | Zentaris Gmbh | Arilcarbonilpiperacinas y heteroarilcarbonilpiperacinas y su uso para tratamiento de enfermedades de tumor benigno y maligno. |
WO2004078732A1 (fr) * | 2003-01-28 | 2004-09-16 | Aventis Pharma S.A. | Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation |
FR2855825B1 (fr) * | 2003-06-04 | 2008-08-22 | Aventis Pharma Sa | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
AR044586A1 (es) * | 2003-06-04 | 2005-09-21 | Aventis Pharma Sa | Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion |
US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
FR2871157A1 (fr) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Produits biaryl aromatiques, compositions les contenant et utilisation |
EP1645556A1 (en) * | 2004-10-07 | 2006-04-12 | Boehringer Ingelheim International GmbH | Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents |
JP2010518014A (ja) * | 2007-01-31 | 2010-05-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用な2−アミノピリジン誘導体 |
US8835426B2 (en) * | 2007-02-26 | 2014-09-16 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
EP2183228B1 (en) * | 2007-07-26 | 2014-08-20 | Vitae Pharmaceuticals, Inc. | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 |
TW200924762A (en) | 2007-11-02 | 2009-06-16 | Vertex Pharma | Kinase inhibitors |
AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
JP5490020B2 (ja) | 2008-01-24 | 2014-05-14 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状カルバゼート及びセミカルバジドインヒビター |
WO2009102428A2 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 |
WO2009102460A2 (en) * | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US20110105504A1 (en) * | 2008-03-18 | 2011-05-05 | Vitae Pharmaceuticals ,Inc. | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 |
EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5301563B2 (ja) | 2008-05-01 | 2013-09-25 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
EP2291373B1 (en) * | 2008-05-01 | 2013-09-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
CA2723039A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
MX2011000837A (es) | 2008-07-23 | 2011-04-05 | Vertex Pharma | Inhibidores de pirazolpiridina cinasa triciclica. |
JP2011529062A (ja) | 2008-07-23 | 2011-12-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピリジンキナーゼ阻害剤 |
NZ590495A (en) | 2008-07-25 | 2012-10-26 | Vitae Pharmaceuticals Inc | Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
TW201016691A (en) | 2008-07-25 | 2010-05-01 | Boehringer Ingelheim Int | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
AU2009279611A1 (en) | 2008-08-06 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Aminopyridine kinase inhibitors |
CA2744946A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
KR20120061771A (ko) * | 2009-04-30 | 2012-06-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
CA2760705A1 (en) | 2009-05-06 | 2010-11-11 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines |
WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2011094290A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
CN102869663A (zh) | 2010-01-27 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 吡唑并吡嗪激酶抑制剂 |
EP2528917B1 (en) | 2010-01-27 | 2016-10-19 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases |
US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン |
CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE791501A (fr) * | 1971-11-19 | 1973-05-17 | Albert Ag Chem Werke | Diamines cycliques n,n'-disubstituees et leur procede de preparation |
JPS50151886A (hu) * | 1974-05-29 | 1975-12-06 | ||
HU175075B (hu) * | 1977-06-30 | 1980-05-28 | Egyt Gyogyszervegyeszeti Gyar | Sposob poluchenija piperazidov piridin-karbonovoj kisloty |
EP0040793B1 (en) * | 1980-05-22 | 1985-08-28 | Masayuki Ishikawa | Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof |
US4937246A (en) * | 1987-11-25 | 1990-06-26 | Takeda Chemical Industries, Ltd. | PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof |
MX16687A (es) * | 1988-07-07 | 1994-01-31 | Ciba Geigy Ag | Compuestos de biarilo y procedimiento para su preparacion. |
WO1995000497A1 (en) * | 1993-06-18 | 1995-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
PL183865B1 (pl) * | 1995-01-11 | 2002-07-31 | Samjin Pharmaceutical Co | Nowe pochodne piperazyny i środek farmaceutyczny |
CA2214685C (en) * | 1995-03-10 | 2008-05-20 | Berlex Laboratories, Inc. | Benzamidine derivatives their preparation and their use as anti-coagulants |
PL325341A1 (en) * | 1996-06-29 | 1998-07-20 | Samjin Pharmaceutical Co | Derivatives od piperazine and method of obtaining them |
ES2125206B1 (es) * | 1997-07-21 | 1999-11-16 | Esteve Labor Dr | Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos. |
AU2793199A (en) * | 1998-02-26 | 1999-09-15 | Neurogen Corporation | 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives,their preparation and their use as (ant-)agonists for gaba (a) brain receptors |
AU772477B2 (en) * | 1998-08-28 | 2004-04-29 | Scios Inc. | Inhibitors of p38-alpha kinase |
AU763030B2 (en) * | 1999-03-03 | 2003-07-10 | Samjin Pharmaceutical Co., Ltd. | Piperazine derivatives and process for the preparation thereof |
US6469006B1 (en) * | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
TR200201568T2 (tr) * | 1999-12-16 | 2002-10-21 | Schering Corporation | İkame edilmiş imidazol nöropeptid Y Y5 reseptörü antagonistleri. |
-
2000
- 2000-07-21 DE DE10035908A patent/DE10035908A1/de not_active Withdrawn
-
2001
- 2001-07-18 HU HU0300743A patent/HUP0300743A2/hu unknown
- 2001-07-18 PL PL36135401A patent/PL361354A1/xx unknown
- 2001-07-18 WO PCT/EP2001/008262 patent/WO2002008190A2/de active IP Right Grant
- 2001-07-18 BR BR0112711-0A patent/BR0112711A/pt not_active IP Right Cessation
- 2001-07-18 IL IL15393101A patent/IL153931A0/xx unknown
- 2001-07-18 NZ NZ524156A patent/NZ524156A/en unknown
- 2001-07-18 CN CN01814312A patent/CN1447796A/zh active Pending
- 2001-07-18 MX MXPA03000596A patent/MXPA03000596A/es unknown
- 2001-07-18 KR KR10-2003-7000880A patent/KR20030015894A/ko not_active Application Discontinuation
- 2001-07-18 JP JP2002514097A patent/JP2004516243A/ja not_active Withdrawn
- 2001-07-18 RU RU2003105238/04A patent/RU2003105238A/ru not_active Application Discontinuation
- 2001-07-18 SK SK194-2003A patent/SK1942003A3/sk not_active Application Discontinuation
- 2001-07-18 EP EP01960509A patent/EP1305289A2/de not_active Withdrawn
- 2001-07-18 AU AU8198901A patent/AU8198901A/xx active Pending
- 2001-07-18 AU AU2001281989A patent/AU2001281989B2/en not_active Ceased
- 2001-07-20 US US09/910,139 patent/US6638935B2/en not_active Expired - Fee Related
- 2001-07-20 CA CA002353353A patent/CA2353353A1/en not_active Abandoned
- 2001-07-20 AR ARP010103479A patent/AR032467A1/es unknown
-
2002
- 2002-01-21 ZA ZA200300545A patent/ZA200300545B/xx unknown
-
2003
- 2003-01-20 NO NO20030302A patent/NO20030302L/no unknown
- 2003-01-30 BG BG107506A patent/BG107506A/bg unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0208190A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU8198901A (en) | 2002-02-05 |
PL361354A1 (en) | 2004-10-04 |
WO2002008190A3 (de) | 2002-08-01 |
WO2002008190A2 (de) | 2002-01-31 |
BR0112711A (pt) | 2003-05-20 |
CN1447796A (zh) | 2003-10-08 |
NO20030302D0 (no) | 2003-01-20 |
SK1942003A3 (en) | 2003-12-02 |
AU2001281989B2 (en) | 2005-05-12 |
KR20030015894A (ko) | 2003-02-25 |
US20020111354A1 (en) | 2002-08-15 |
HUP0300743A2 (hu) | 2003-10-28 |
JP2004516243A (ja) | 2004-06-03 |
BG107506A (bg) | 2003-09-30 |
US6638935B2 (en) | 2003-10-28 |
NZ524156A (en) | 2005-10-28 |
MXPA03000596A (es) | 2003-05-14 |
IL153931A0 (en) | 2003-07-31 |
DE10035908A1 (de) | 2002-03-07 |
RU2003105238A (ru) | 2004-08-10 |
ZA200300545B (en) | 2003-02-12 |
NO20030302L (no) | 2003-02-07 |
AR032467A1 (es) | 2003-11-12 |
CA2353353A1 (en) | 2002-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1305289A2 (de) | Neue heteroaryl-derivate und deren verwendung als antitumormittel | |
EP1301485B1 (de) | Acridin-derivate und deren verwendung als arzneimittel | |
WO2002008192A1 (de) | Neue heteroaryl-derivate und deren verwendung als arzneimittel | |
EP0527736B1 (de) | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung | |
WO2002010152A2 (de) | Neue indolderivate und deren verwendung als arzneimittel | |
DE69932920T2 (de) | Neue dihydroxyhexansäurederivate | |
EP0769296B1 (de) | Verwendung eines Natrium- oder Lysiniumsalzes von Crotonsäureamidderivaten zur Herstellung eines Arzneimittels zur Behandlung von Krebserkrankungen | |
DE3416695A1 (de) | Amidinohydrazone von tetralin-, chromon-, thiochromon- und tretrahydrochinolin-derivaten, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln | |
DE19506742A1 (de) | Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen | |
DE3790581B4 (de) | Verfahren zur selektiven Vernichtung von hypoxischen Tumorzellen | |
EP1521748A1 (de) | Neue anthracen-derivate und deren verwendung als arzneimittel | |
DE69819192T2 (de) | Neue cyanoaziridine zur behandlung von krebs | |
DE1813918C3 (de) | 2-Hydroxymethyl-3-carbonsäureamido--chinoxalin-M-di-N-oxide, ein Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende antibakterielle Mittel | |
EP0442348B1 (de) | Neue Imidazolverbindungen, Verfahren zu deren Herstellung, Arzneimittel auf Basis dieser Verbindungen sowie einige Zwischenprodukte | |
DE3745196B4 (de) | Verbindungen und deren Verwendung zur selektiven Vernichtung von hypoxischen Tumorzellen | |
DD275241A5 (de) | Verfahren zur herstellung von neuen 1-aryloxy-3-amimo-2-propanolen | |
DE2839224C2 (hu) | ||
DE1443376C3 (de) | Verfahren zur Herstellung von 2-Amino-alpha-substituierten Benzylidenaminen, sowie neue 2-Amino-alpha-substituierte Benzylidenamine als solche | |
DE10232525A1 (de) | Neue Anthracen-Derivate und deren Verwendung als Arzneimittel | |
CH616672A5 (en) | Process for the preparation of novel cyclic imides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030109 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ZENTARIS GMBH |
|
17Q | First examination report despatched |
Effective date: 20050124 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20051007 |